IBDEI1LG ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,28291,1,4,0)
 ;;=4^V15.84
 ;;^UTILITY(U,$J,358.3,28291,1,5,0)
 ;;=5^Hx Of Asbestos Exposure
 ;;^UTILITY(U,$J,358.3,28291,2)
 ;;=^303406
 ;;^UTILITY(U,$J,358.3,28292,0)
 ;;=V15.85^^162^1794^47
 ;;^UTILITY(U,$J,358.3,28292,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,28292,1,4,0)
 ;;=4^V15.85
 ;;^UTILITY(U,$J,358.3,28292,1,5,0)
 ;;=5^Hx Of Potentially Hazardous Body Fluids
 ;;^UTILITY(U,$J,358.3,28292,2)
 ;;=^303407
 ;;^UTILITY(U,$J,358.3,28293,0)
 ;;=V10.72^^162^1794^32
 ;;^UTILITY(U,$J,358.3,28293,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,28293,1,4,0)
 ;;=4^V10.72
 ;;^UTILITY(U,$J,358.3,28293,1,5,0)
 ;;=5^Hx Of Hodgkin's Disease
 ;;^UTILITY(U,$J,358.3,28293,2)
 ;;=^295237
 ;;^UTILITY(U,$J,358.3,28294,0)
 ;;=V15.3^^162^1794^33
 ;;^UTILITY(U,$J,358.3,28294,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,28294,1,4,0)
 ;;=4^V15.3
 ;;^UTILITY(U,$J,358.3,28294,1,5,0)
 ;;=5^Hx Of Irradiation
 ;;^UTILITY(U,$J,358.3,28294,2)
 ;;=^295285
 ;;^UTILITY(U,$J,358.3,28295,0)
 ;;=V10.61^^162^1794^36
 ;;^UTILITY(U,$J,358.3,28295,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,28295,1,4,0)
 ;;=4^V10.61
 ;;^UTILITY(U,$J,358.3,28295,1,5,0)
 ;;=5^Hx Of Lymphoid Leukemia
 ;;^UTILITY(U,$J,358.3,28295,2)
 ;;=Hx of Lymphoid Leukemia^295232
 ;;^UTILITY(U,$J,358.3,28296,0)
 ;;=V12.03^^162^1794^38
 ;;^UTILITY(U,$J,358.3,28296,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,28296,1,4,0)
 ;;=4^V12.03
 ;;^UTILITY(U,$J,358.3,28296,1,5,0)
 ;;=5^Hx Of Malaria
 ;;^UTILITY(U,$J,358.3,28296,2)
 ;;=Hx of Malaria^303395
 ;;^UTILITY(U,$J,358.3,28297,0)
 ;;=V10.82^^162^1794^39
 ;;^UTILITY(U,$J,358.3,28297,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,28297,1,4,0)
 ;;=4^V10.82
 ;;^UTILITY(U,$J,358.3,28297,1,5,0)
 ;;=5^Hx Of Malignant Melanoma
 ;;^UTILITY(U,$J,358.3,28297,2)
 ;;=Hx of Malignant Melanoma^295240
 ;;^UTILITY(U,$J,358.3,28298,0)
 ;;=V10.62^^162^1794^42
 ;;^UTILITY(U,$J,358.3,28298,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,28298,1,4,0)
 ;;=4^V10.62
 ;;^UTILITY(U,$J,358.3,28298,1,5,0)
 ;;=5^Hx Of Myeloid Leukemia
 ;;^UTILITY(U,$J,358.3,28298,2)
 ;;=Hx of Myeloid Leukemia^295233
 ;;^UTILITY(U,$J,358.3,28299,0)
 ;;=V10.63^^162^1794^40
 ;;^UTILITY(U,$J,358.3,28299,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,28299,1,4,0)
 ;;=4^V10.63
 ;;^UTILITY(U,$J,358.3,28299,1,5,0)
 ;;=5^Hx Of Monocytic Leukemia
 ;;^UTILITY(U,$J,358.3,28299,2)
 ;;=Hx of Monocytic Leukemia^295234
 ;;^UTILITY(U,$J,358.3,28300,0)
 ;;=V11.2^^162^1794^30
 ;;^UTILITY(U,$J,358.3,28300,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,28300,1,4,0)
 ;;=4^V11.2
 ;;^UTILITY(U,$J,358.3,28300,1,5,0)
 ;;=5^Hx Of Dysthymia
 ;;^UTILITY(U,$J,358.3,28300,2)
 ;;=Hx of Dysthymia^295251
 ;;^UTILITY(U,$J,358.3,28301,0)
 ;;=V15.81^^162^1794^60
 ;;^UTILITY(U,$J,358.3,28301,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,28301,1,4,0)
 ;;=4^V15.81
 ;;^UTILITY(U,$J,358.3,28301,1,5,0)
 ;;=5^Noncompliance With Medical Treatment
 ;;^UTILITY(U,$J,358.3,28301,2)
 ;;=^295290
 ;;^UTILITY(U,$J,358.3,28302,0)
 ;;=V10.43^^162^1794^43
 ;;^UTILITY(U,$J,358.3,28302,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,28302,1,4,0)
 ;;=4^V10.43
 ;;^UTILITY(U,$J,358.3,28302,1,5,0)
 ;;=5^Hx Of Ovarian Ca
 ;;^UTILITY(U,$J,358.3,28302,2)
 ;;=Hx of Ovarian CA^295221
 ;;^UTILITY(U,$J,358.3,28303,0)
 ;;=V12.71^^162^1794^45
 ;;^UTILITY(U,$J,358.3,28303,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,28303,1,4,0)
 ;;=4^V12.71
 ;;^UTILITY(U,$J,358.3,28303,1,5,0)
 ;;=5^Hx Of Peptic Ulcer Disease
 ;;^UTILITY(U,$J,358.3,28303,2)
 ;;=^303400
 ;;^UTILITY(U,$J,358.3,28304,0)
 ;;=V10.46^^162^1794^48
 ;;^UTILITY(U,$J,358.3,28304,1,0)
 ;;=^358.31IA^5^2
 ;;
 ;;$END ROU IBDEI1LG
